Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
AEON BIOPHARMA INC (AEON)
AMEXHealth CareBiotechnologySnapshot 2026-11-04
$0.16-24.21%
Close 2026-11-05 · 1-day change
AMEXHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for AEON yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Complete private placement and manage capital effectively | The company completed a private placement to support capital needs. | Intact | Private placement not completed by mid-2026 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 13, 2026
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
AEON is a high-risk development-stage business, not an established earnings compounder. Its thesis is on watch: management has reported regulatory progress for ABP-450 and secured near-term funding, but the supplied evidence does not show revenue or demonstrated development delivery.
The evidence is too thin to assess whether AEON is cheap, fair, or expensive versus peers, or to establish what expectations are already reflected in its valuation. Its loss-making status and weak recent performance point to a difficult fundamental setup, while the improving Healthcare sector backdrop is a supportive factor rather than proof of company-level value.
Near term, results remain hard to rely on: the company is loss-making, recent performance is weak, and the next-print miss risk is flagged as elevated. Operating expenses rose year over year in 2026-Q2, and the available figures do not report revenue; management cites ABP-450 regulatory steps and July financing expected to fund operations into 2027-Q1. Litigation filings add risk, despite the reported earnings beat and regained listing compliance.
The multi-year thesis depends on ABP-450 advancing beyond stated regulatory steps and on AEON maintaining enough funding to continue operations. Near term, a guidance cut or further weakening in jobs data could pressure the business context, while stronger results and guidance from Healthcare bellwethers could support sector momentum. The evidence is low confidence, so these signals need follow-through.
Over the next 1 to 3 years, AEON remains a watch-stage, high-risk development story with limited financial proof and near-term funding secured, but continued capital access and execution remain central uncertainties. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| It aims to manage cash flow and reduce losses. |
| Broken |
| Operating loss remains above $5M per quarter |
Operating income: $-5.919M FY2026-Q2; GAAP. Published target: Operating loss improves to less than $4M per quarter. Reported actuals cannot certify a consensus target without an explicit period and accounting-basis binding. Aug 12, 2026-5,919,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Resolve NYSE American listing compliance issues | AEON is working to fix NYSE compliance issues. | Recovered | Non-compliance persists beyond FY26 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-30.24 → $-0.28 · observed estimates
$0.00B → $0.00B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-30.24 | $2,360,000 | 1 / 1 |
| 2026-07-25 | $-30.24 | $2,360,000 | 1 / 1 |
| 2026-07-26 | $-30.24 | $2,360,000 | 1 / 1 |
| 2026-07-27 | $-30.24 | $2,360,000 | 1 / 1 |
| 2026-07-28 | Unavailable | $0 | — / 1 |
| 2026-07-29 | Unavailable | $0 | — / 1 |
| 2026-07-30 | Unavailable | $0 | — / 1 |
| 2026-07-31 | $-0.52 | $0 | 1 / 2 |
| 2026-08-01 | $-0.52 | $0 | 1 / 2 |
| 2026-08-02 | $-0.52 | $0 | 1 / 2 |
| 2026-08-03 | $-0.52 | $0 | 1 / 2 |
| 2026-08-04 | $-0.52 | $0 | 1 / 2 |
| 2026-08-05 | $-0.52 | $0 | 1 / 2 |
| 2026-08-06 | $-0.52 | $0 | 1 / 2 |
| 2026-08-07 | $-0.52 | $0 | 1 / 2 |
| 2026-08-08 | $-0.52 | $0 | 1 / 2 |
| 2026-08-09 | $-0.52 | $0 | 1 / 2 |
| 2026-08-10 | $-0.52 | $0 | 1 / 2 |
| 2026-08-11 | $-0.52 | $0 | 1 / 2 |
| 2026-08-12 | $-0.52 | $0 | 1 / 2 |
| 2026-08-13 | $-0.52 | $0 | 1 / 2 |
| 2026-08-14 | $-0.52 | $2,360,000 | 1 / 2 |
| 2026-08-15 | $-0.52 | $2,360,000 | 1 / 2 |
| 2026-08-16 | $-0.52 | $2,360,000 | 1 / 2 |
| 2026-08-17 | $-0.52 | $2,360,000 | 1 / 2 |
| 2026-08-18 | $-0.52 | $2,360,000 | 1 / 2 |
| 2026-08-19 | $-0.52 | $2,360,000 | 1 / 2 |
| 2026-08-20 | $-0.39 | $1,180,000 | 1 / 2 |
| 2026-08-21 | $-0.39 | $1,180,000 | 1 / 2 |
| 2026-08-22 | $-0.39 | $1,180,000 | 1 / 2 |
| 2026-08-23 | $-0.39 | $1,180,000 | 1 / 2 |
| 2026-08-24 | $-0.39 | $1,180,000 | 1 / 2 |
| 2026-08-25 | $-0.39 | $1,180,000 | 1 / 2 |
| 2026-08-26 | $-0.39 | $1,180,000 | 1 / 2 |
| 2026-08-27 | $-0.39 | $1,180,000 | 1 / 2 |
| 2026-08-28 | $-0.39 | $1,180,000 | 1 / 2 |
| 2026-08-29 | $-0.39 | $1,180,000 | 1 / 2 |
| 2026-08-30 | $-0.39 | $1,180,000 | 1 / 2 |
| 2026-08-31 | $-0.39 | $1,180,000 | 1 / 2 |
| 2026-09-01 | $-0.39 | $1,180,000 | 1 / 2 |
| 2026-09-02 | $-0.39 | $1,180,000 | 1 / 2 |
| 2026-09-03 | $-0.39 | $1,180,000 | 1 / 2 |
| 2026-09-04 | $-0.39 | $1,180,000 | 1 / 2 |
| 2026-09-05 | $-0.39 | $1,180,000 | 1 / 2 |
| 2026-09-06 | $-0.39 | $1,180,000 | 1 / 2 |
| 2026-09-07 | $-0.39 | $1,180,000 | 1 / 2 |
| 2026-09-08 | $-0.39 | $1,180,000 | 1 / 2 |
| 2026-09-09 | $-0.39 | $1,180,000 | 1 / 2 |
| 2026-09-10 | $-0.36 | $1,180,000 | 1 / 2 |
| 2026-09-11 | $-0.36 | $1,180,000 | 1 / 2 |
| 2026-09-12 | $-0.36 | $1,180,000 | 1 / 2 |
| 2026-09-13 | $-0.36 | $1,180,000 | 1 / 2 |
| 2026-09-14 | $-0.36 | $1,180,000 | 1 / 2 |
| 2026-09-15 | $-0.36 | $1,180,000 | 1 / 2 |
| 2026-09-16 | $-0.36 | $1,180,000 | 1 / 2 |
| 2026-09-17 | $-0.36 | $1,180,000 | 1 / 2 |
| 2026-09-18 | $-0.36 | $1,180,000 | 1 / 2 |
| 2026-09-19 | $-0.36 | $1,180,000 | 1 / 2 |
| 2026-09-20 | $-0.36 | $1,180,000 | 1 / 2 |
| 2026-09-21 | $-0.36 | $1,180,000 | 1 / 2 |
| 2026-09-22 | $-0.36 | $1,180,000 | 1 / 2 |
| 2026-09-23 | $-0.36 | $1,180,000 | 1 / 3 |
| 2026-09-24 | $-0.36 | $1,180,000 | 1 / 3 |
| 2026-09-25 | $-0.36 | $1,180,000 | 1 / 2 |
| 2026-09-26 | $-0.36 | $1,180,000 | 1 / 3 |
| 2026-09-27 | $-0.36 | $1,180,000 | 1 / 3 |
| 2026-09-28 | $-0.36 | $1,180,000 | 1 / 3 |
| 2026-09-29 | $-0.36 | $1,180,000 | 1 / 3 |
| 2026-09-30 | $-0.36 | $1,180,000 | 1 / 3 |
| 2026-10-01 | $-0.36 | $1,180,000 | 1 / 3 |
| 2026-10-02 | $-0.30 | $1,180,000 | 1 / 3 |
| 2026-10-03 | $-0.30 | $1,180,000 | 1 / 3 |
| 2026-10-04 | $-0.30 | $1,180,000 | 1 / 3 |
| 2026-10-05 | $-0.30 | $1,180,000 | 1 / 3 |
| 2026-10-06 | $-0.30 | $1,180,000 | 1 / 3 |
| 2026-10-07 | $-0.28 | $786,667 | 2 / 3 |
| 2026-10-08 | $-0.28 | $786,667 | 2 / 3 |
| 2026-10-09 | $-0.28 | $786,667 | 2 / 3 |
| 2026-10-10 | $-0.28 | $786,667 | 2 / 3 |
| 2026-10-11 | $-0.28 | $786,667 | 2 / 3 |
| 2026-10-12 | $-0.28 | $786,667 | 2 / 3 |
| 2026-10-13 | $-0.28 | $786,667 | 2 / 3 |
| 2026-10-14 | $-0.28 | $786,667 | 2 / 3 |
| 2026-10-15 | $-0.28 | $786,667 | 2 / 3 |
| 2026-10-16 | $-0.28 | $786,667 | 2 / 3 |
| 2026-10-17 | $-0.28 | $786,667 | 2 / 3 |
| 2026-10-18 | $-0.28 | $786,667 | 2 / 3 |
| 2026-10-19 | $-0.28 | $786,667 | 2 / 3 |
| 2026-10-20 | $-0.28 | $786,667 | 2 / 3 |
| 2026-10-21 | $-0.28 | $786,667 | 2 / 3 |
| 2026-10-22 | $-0.28 | $786,667 | 2 / 3 |
| 2026-10-23 | $-0.28 | $786,667 | 2 / 3 |
| 2026-10-24 | $-0.28 | $786,667 | 2 / 3 |
| 2026-10-25 | $-0.28 | $786,667 | 2 / 3 |
| 2026-10-26 | $-0.28 | $786,667 | 2 / 3 |
| 2026-10-27 | $-0.28 | $786,667 | 2 / 3 |
| 2026-10-28 | $-0.28 | $786,667 | 2 / 3 |
| 2026-10-29 | $-0.28 | $786,667 | 2 / 3 |
| 2026-10-30 | $-0.28 | $786,667 | 2 / 3 |
| 2026-10-31 | $-0.28 | $786,667 | 2 / 3 |
| 2026-11-01 | $-0.28 | $786,667 | 2 / 3 |
| 2026-11-02 | $-0.28 | $786,667 | 2 / 3 |
| 2026-11-03 | $-0.28 | $786,667 | 2 / 3 |
| 2026-11-04 | $-0.28 | $786,667 | 2 / 3 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 4 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.